These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 9928900)

  • 21. Posterior orbitofrontal sulcogyral pattern associated with orbitofrontal cortex volume reduction and anxiety trait in panic disorder.
    Roppongi T; Nakamura M; Asami T; Hayano F; Otsuka T; Uehara K; Fujiwara A; Saeki T; Hayasaka S; Yoshida T; Shimizu R; Inoue T; Hirayasu Y
    Psychiatry Clin Neurosci; 2010 Jun; 64(3):318-26. PubMed ID: 20602731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regional brain volume in depression and anxiety disorders.
    van Tol MJ; van der Wee NJ; van den Heuvel OA; Nielen MM; Demenescu LR; Aleman A; Renken R; van Buchem MA; Zitman FG; Veltman DJ
    Arch Gen Psychiatry; 2010 Oct; 67(10):1002-11. PubMed ID: 20921116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.
    Zwanzger P; Rupprecht R
    J Psychiatry Neurosci; 2005 May; 30(3):167-75. PubMed ID: 15944741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asymmetry of prefrontal cortex activities and catechol-O-methyltransferase Val158Met genotype in patients with panic disorder during a verbal fluency task: near-infrared spectroscopy study.
    Tanii H; Nishimura Y; Inoue K; Koshimizu H; Matsumoto R; Takami T; Hara N; Nishida A; Okada M; Kaiya H; Okazaki Y
    Neurosci Lett; 2009 Mar; 452(1):63-7. PubMed ID: 19429001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased gray matter volume of the medial orbitofrontal cortex in panic disorder with agoraphobia: a preliminary study.
    Na KS; Ham BJ; Lee MS; Kim L; Kim YK; Lee HJ; Yoon HK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():195-200. PubMed ID: 23628432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: clinical issues and future directions.
    Bradwejn J
    Can J Psychiatry; 1993 Nov; 38 Suppl 4():S109-13. PubMed ID: 7905780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between the prefrontal function during a cognitive task and the severity of the symptoms in patients with panic disorder: a multi-channel NIRS study.
    Nishimura Y; Tanii H; Hara N; Inoue K; Kaiya H; Nishida A; Okada M; Okazaki Y
    Psychiatry Res; 2009 May; 172(2):168-72. PubMed ID: 19324535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Common limbic and frontal-striatal disturbances in patients with obsessive compulsive disorder, panic disorder and hypochondriasis.
    van den Heuvel OA; Mataix-Cols D; Zwitser G; Cath DC; van der Werf YD; Groenewegen HJ; van Balkom AJ; Veltman DJ
    Psychol Med; 2011 Nov; 41(11):2399-410. PubMed ID: 21557892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Health-related quality of life assessment in depression after low-frequency transcranial magnetic stimulation].
    Dumas R; Boyer L; Richieri R; Guedj E; Auquier P; Lançon C
    Encephale; 2014 Feb; 40(1):74-80. PubMed ID: 24091070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment.
    Cowley DS; Roy-Byrne PP; Radant A; Ritchie JC; Greenblatt DJ; Nemeroff CB; Hommer DW
    Neuropsychopharmacology; 1995 Apr; 12(2):147-57. PubMed ID: 7779243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What do brain imaging studies tell us about anxiety disorders?
    Malizia AL
    J Psychopharmacol; 1999 Dec; 13(4):372-8. PubMed ID: 10667613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age-related increase in GABAA receptor distribution in the prefrontal cortex.
    Tobinaga M; Suzuki Y; Fujinaka H; Ozawa T; Nakajima T
    J Clin Neurosci; 2019 Jun; 64():106-110. PubMed ID: 30948309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Approaching the molecular pathology of suicide.
    Akbarian S
    Biol Psychiatry; 2008 Oct; 64(8):643-644. PubMed ID: 18926170
    [No Abstract]   [Full Text] [Related]  

  • 34. Glutamate changes in anterior cingulate cortex following CCK-4 infusion.
    Maddock RJ
    Neuropsychopharmacology; 2014 Oct; 39(11):2706. PubMed ID: 24939759
    [No Abstract]   [Full Text] [Related]  

  • 35. Panic disorder, alcohol and substance abuse, and benzodiazepine prescription.
    Sansone RA; Griffith KA; Sansone LA
    Prim Care Companion J Clin Psychiatry; 2005; 7(5):246-8. PubMed ID: 16308586
    [No Abstract]   [Full Text] [Related]  

  • 36. Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder.
    Dresler T; Guhn A; Tupak SV; Ehlis AC; Herrmann MJ; Fallgatter AJ; Deckert J; Domschke K
    J Neural Transm (Vienna); 2013 Jan; 120(1):3-29. PubMed ID: 22692647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results.
    Klumpers UM; Veltman DJ; Drent ML; Boellaard R; Comans EF; Meynen G; Lammertsma AA; Hoogendijk WJ
    Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):565-74. PubMed ID: 19890631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroimaging in anxiety disorders.
    Engel K; Bandelow B; Gruber O; Wedekind D
    J Neural Transm (Vienna); 2009 Jun; 116(6):703-16. PubMed ID: 18568288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The molecular neuroimaging of anxiety disorders.
    Talbot PS
    Curr Psychiatry Rep; 2004 Aug; 6(4):274-9. PubMed ID: 15260943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased benzodiazepine receptor density in the prefrontal cortex in patients with panic disorder.
    Brandt CA; Meller J; Keweloh L; Höschel K; Staedt J; Munz D; Stoppe G
    J Neural Transm (Vienna); 1998; 105(10-12):1325-33. PubMed ID: 9928900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.